A Natural Fungal Supplement Enhances COVID-19 Vaccine Efficacy
A groundbreaking study from the University of California San Diego School of Medicine has revealed a natural fungal supplement's potential to revolutionize COVID-19 vaccine efficacy. The research, published in BMC Immunology, demonstrates that this supplement, derived from the mycelium of two medicinal fungi, significantly reduces short-term vaccine side effects and enhances antibody durability in individuals who have not been previously exposed to the virus.
The study, a randomized, double-blind, placebo-controlled clinical trial, involved 90 adults receiving a COVID-19 vaccine. Participants were randomly assigned to take either the fungal supplement or placebo capsules for four days, starting on the day of vaccination. The results were remarkable.
The strongest benefits were observed in 'COVID-naïve' participants, those who had never had COVID-19 and had not been vaccinated before joining the study. These individuals experienced significantly fewer side effects after vaccination compared to those taking the placebo. Moreover, antibody levels in the supplement group continued to rise over the six-month study period, unlike the typical post-vaccination antibody decline.
Gordon Saxe, MD, PhD, MPH, the study's principal investigator, emphasized the significance of these findings. He stated, 'Our goal was to see whether FoTv, a possible natural immune regulator, could decrease vaccine side effects while preserving or increasing antibody levels and helping vaccine protection last longer. The results suggest that it may have done both.'
The study's implications are far-reaching. By reducing side effects and improving antibody durability, this natural supplement could potentially alleviate vaccine hesitancy and reduce the need for frequent booster shots. This is particularly crucial in the face of emerging infectious threats like H5N1 avian influenza.
The fungal mycelium, grown using standardized, scalable, and medical-grade production methods, offers a promising approach to strengthening vaccines without increasing side effects. Saxe added, 'With emerging infectious threats such as H5N1 avian influenza on the horizon, we need affordable and rapidly scalable tools that can strengthen vaccines without increasing their side effects. This study shows that FoTv, a carefully tested natural immune modulator, may help support that goal.'
However, Saxe also stressed the need for additional studies to confirm the findings and fully understand the supplement's mechanism of action. The study was funded by various grants, and the authors declare no competing interests, except for Saxe's role on the board of the Krupp Endowed Fund, from which he recused himself during the decision-making process.
The study's co-authors include experts from UC San Diego School of Medicine, UC Irvine, Fungi Perfecti, LLC, UCLA, and the Botnar Institute of Immune Engineering. The mushroom mycelium used in the study was provided by Fungi Perfecti, LLC, and the authors express no conflicts of interest.
The full study is available at the following link: [https://link.springer.com/article/10.1186/s12865-026-00809-9].
This research highlights the potential of natural products in enhancing vaccine efficacy and opens up new avenues for exploration in the field of immunology.
